Literature DB >> 12845646

Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells.

Stefano Buttiglieri1, Alessandra Galetto, Sarah Forno, Marco De Andrea, Lina Matera.   

Abstract

Here we have studied the effects of apoptotic cell death induced by chemotherapic agents on tumor phagocytosis by dendritic cells (DC) and presentation of the relevant antigen to T lymphocytes. Annexin-V-FITC (Ann-V) and propidium iodide (PI) staining was used to assess early apoptotic (Ann-V(+)/PI(-)) vs. late apoptotic/secondary necrotic (Ann-V(+)/PI(+)) death after a 24 hr observation of untreated and drug-treated gastric carcinoma cells. After treatments, the HLA-A*0201(+) tumor cell line KATO III was exposed for 24 hr to allogeneic, HLA-related GM-CSF, IL-4-driven immature (i) DC. Tumor-loaded iDC were tested for IL-12 release in an ELISA assay, incubated with the DC-maturating factor TNF-alpha and used as stimulators for autologous T lymphocytes. Generation of antitumor T response against KATO cells was evaluated in an anti-MHC class I MAb-blocked Interferon-gamma ELISPOT assay. After treatment with Cis-platin (cis), all dying cells were in early apoptosis, whereas secondary necrosis was the prevalent death pattern observed after epirubicin (epi) and doxorubicin (doxo). Doxo and epi increased tumor expression of heat shock protein (hsp) 70 and uptake of tumor cell components by DC, whereas cis treatment had no effect on hsp70 and was associated with poor tumor uptake by DC. Significant upmodulation of IL-12 was observed by DC that had taken up the doxo- and epi-treated tumors (p< 0.005 and p< 0.01, respectively). Increased IFN-gamma release was also observed after stimulation of T lymphocytes with DC loaded with doxo- and epi-treated (p< 0.02 and p< 0.005, respectively) but not with cis-treated DC. These data show that the products of early apoptosis cannot efficiently cross-activate MHC class I-restricted anti-tumor lymphocytes even in the presence of DC maturating factors, whereas secondary necrosis is associated with robust T cell response. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845646     DOI: 10.1002/ijc.11243

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Authors:  Lukas W Pfannenstiel; Samuel S K Lam; Leisha A Emens; Elizabeth M Jaffee; Todd D Armstrong
Journal:  Cell Immunol       Date:  2010-03-06       Impact factor: 4.868

Review 2.  Natural endogenous adjuvants.

Authors:  Kenneth L Rock; Arron Hearn; Chun-Jen Chen; Yan Shi
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

3.  Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.

Authors:  Paul Hatfield; Alison E Merrick; Emma West; Dearbhaile O'Donnell; Peter Selby; Richard Vile; Alan A Melcher
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

4.  Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.

Authors:  Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

5.  Activated apoptotic cells induce dendritic cell maturation via engagement of Toll-like receptor 4 (TLR4), dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), and β2 integrins.

Authors:  Sushil Kumar Pathak; Annette E Sköld; Venkatramanan Mohanram; Catrine Persson; Ulrika Johansson; Anna-Lena Spetz
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

6.  Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs.

Authors:  Zhenlin Hu; Xiao Yi Yang; Yunbo Liu; Michael A Morse; H Kim Lyerly; Timothy M Clay; Pei Zhong
Journal:  Biochem Biophys Res Commun       Date:  2005-09-16       Impact factor: 3.575

7.  Differential effects of Paclitaxel on dendritic cell function.

Authors:  Justin John; Mohammed Ismail; Catherine Riley; Jonathan Askham; Richard Morgan; Alan Melcher; Hardev Pandha
Journal:  BMC Immunol       Date:  2010-03-19       Impact factor: 3.615

8.  Effect of prolactin on carcinoembryonic antigen-specific cytotoxic T lymphocyte response induced by dendritic cells.

Authors:  L Matera; E Beltramo; E Martinuzzi; S Buttiglieri
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

9.  Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.

Authors:  Terry R Medler; Tiziana Cotechini; Lisa M Coussens
Journal:  Trends Cancer       Date:  2015-09-01

Review 10.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.